



Antiviral Drug Development for the Treatment of Human Coronavirus

Guest Editors:

Prof. Dr. Xingyue Ji

Prof. Dr. Yuhuan Li

Prof. Dr. Jiangning Liu

Deadline for manuscript
submissions:

closed (31 December 2021)

Message from the Guest Editors

Viral infections still represent one major threat to human health. The coronavirus disease (COVID-19) pandemic has already claimed the lives of more than three million people worldwide and had a huge impact on everyone's daily lifestyle. Chiefly, similar to other RNA viruses, high mutation rates will make SARS-CoV-2 so cunning as to evade the attack of antibodies. According to a recent study, more than 12,000 mutations in SARS-CoV-2 genomes have been identified. Therefore, developing antiviral agents against SARS-CoV-2 is still in high demand. In this Special Issue, we aim to collect a series of high-quality reviews and research papers on antiviral drug development against human coronavirus. The scope includes but is not limited to structure-activity relationship studies, drug screening, drug repurposing, diagnosis and mechanism of action. In addition, we know that most of the institutions do not have the facility to conduct the activity test for highly pathogenic viruses such as SARS-CoV-2, so research papers dealing with any human coronavirus are also welcomed, especially the ones reporting broad-spectrum antiviral activities.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical
Biology and Phytochemistry,
University of Münster,
Corrensstrasse 48, D-48149
Münster, Germany

Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [MEDLINE](#), [PMC](#), [Reaxys](#), [CaPlus / SciFinder](#), [MarinLit](#), [AGRIS](#), and [other databases](#).

Journal Rank: JCR - Q2 (Chemistry, Multidisciplinary) / CiteScore - Q1 (Chemistry (miscellaneous))

Contact Us

Molecules Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/molecules
molecules@mdpi.com
[X@Molecules_MDPI](#)